Kinnear Ned, Heijkoop Bridget, Hua Lina, Hennessey Derek B, Spernat Daniel
Department of Urology, The Queen Elizabeth Hospital, Adelaide, Australia.
Department of Urology, Craigavon Area Hospital, Portadown, UK.
Transl Androl Urol. 2018 May;7(Suppl 2):S179-S187. doi: 10.21037/tau.2018.04.19.
To examine the effect of intra-operative cell salvage (ICS) in open radical prostatectomy.
In this retrospective cohort study, all patients undergoing open radical prostatectomy for malignancy at our institution between 10/04/2013 and 10/04/2017 were enrolled. Patients were grouped and compared based on whether they received ICS. Primary outcomes were allogeneic transfusion rates, and disease recurrence. Secondary outcomes were complications and transfusion-related cost.
Fifty-nine men were enrolled; 30 used no blood conservation technique, while 29 employed ICS. There were no significant differences between groups in age, pre- or post-operative haemoglobin, Charlson comorbidity index, operation duration or length of stay. Tumour characteristics were also similar between groups, including pre-operative prostate specific antigen, post-operative Gleason score, T-stage, nodal status and rates of margin positivity. Compared with controls, the ICS group had longer follow up (945 989 days; P=0.0016). The control and ICS groups were not significantly different in rates of tumour recurrence (6 3 patients; P=0.30) or complications (10 5 patients; P=0.16). While the proportion of patients receiving allogenic transfusion was similar (9 6 patients; P=0.41), fewer red blood products transfused (40 12 units) meant transfusion related costs were lower in ICS patients (AUD $47,666 $37,429).
ICS reduced transfusion related costs, without affecting allogeneic transfusion rates, tumour recurrence or complication rates. These findings extend the literature supporting ICS in oncological surgery. Prospective randomised studies are needed to confirm the existing level III evidence.
探讨术中细胞回收(ICS)在开放性根治性前列腺切除术中的作用。
在这项回顾性队列研究中,纳入了2013年4月10日至2017年4月10日期间在我院接受开放性根治性前列腺切除术治疗恶性肿瘤的所有患者。根据患者是否接受ICS进行分组并比较。主要结局指标为异体输血率和疾病复发情况。次要结局指标为并发症和输血相关费用。
共纳入59名男性患者;30名未采用血液保护技术,29名采用了ICS。两组在年龄、术前或术后血红蛋白水平、查尔森合并症指数、手术时长或住院时间方面无显著差异。两组的肿瘤特征也相似,包括术前前列腺特异性抗原、术后Gleason评分、T分期、淋巴结状态及切缘阳性率。与对照组相比,ICS组的随访时间更长(945±989天;P = 0.0016)。对照组和ICS组在肿瘤复发率(6±3例患者;P = 0.30)或并发症发生率(10±5例患者;P = 0.16)方面无显著差异。虽然接受异体输血的患者比例相似(9±6例患者;P = 0.41),但ICS组输注的红细胞制品较少(40±12单位),这意味着ICS组患者的输血相关费用较低(47,666澳元±37,429澳元)。
ICS降低了输血相关费用,且不影响异体输血率、肿瘤复发率或并发症发生率。这些发现扩展了支持在肿瘤手术中应用ICS的文献。需要进行前瞻性随机研究以证实现有的III级证据。